Atea Enterprise Value vs Tangible Asset Value Analysis
AVIR Stock | USD 3.67 0.05 1.34% |
Atea PharmaceuticalsI financial indicator trend analysis is way more than just evaluating Atea PharmaceuticalsInc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Atea PharmaceuticalsInc is a good investment. Please check the relationship between Atea PharmaceuticalsI Enterprise Value and its Tangible Asset Value accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
Enterprise Value vs Tangible Asset Value
Enterprise Value vs Tangible Asset Value Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Atea PharmaceuticalsInc Enterprise Value account and Tangible Asset Value. At this time, the significance of the direction appears to have no relationship.
The correlation between Atea PharmaceuticalsI's Enterprise Value and Tangible Asset Value is 0.0. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Tangible Asset Value in the same time period over historical financial statements of Atea PharmaceuticalsInc, assuming nothing else is changed. The correlation between historical values of Atea PharmaceuticalsI's Enterprise Value and Tangible Asset Value is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Atea PharmaceuticalsInc are associated (or correlated) with its Tangible Asset Value. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Tangible Asset Value has no effect on the direction of Enterprise Value i.e., Atea PharmaceuticalsI's Enterprise Value and Tangible Asset Value go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Enterprise Value
Enterprise Value (or EV) is usually referred to as Atea PharmaceuticalsI theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Atea PharmaceuticalsInc debt, but would also pocket its cash. Enterprise Value is more accurate representation of Atea PharmaceuticalsI value than its market capitalization because it takes into account all of Atea PharmaceuticalsInc existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Most indicators from Atea PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Atea PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. As of 04/23/2024, Selling General Administrative is likely to drop to about 31.8 M. In addition to that, Tax Provision is likely to drop to about 967.1 K
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 213K | 11.2M | 29.2M | 30.7M | Net Interest Income | 213K | 11.2M | 29.2M | 30.7M |
Atea PharmaceuticalsI fundamental ratios Correlations
Click cells to compare fundamentals
Atea PharmaceuticalsI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atea PharmaceuticalsI fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 22.1M | 863.6M | 772.9M | 666.7M | 595.0M | 541.8M | |
Other Current Liab | 1.9M | 14.4M | 52.3M | 15.2M | 27.4M | 20.6M | |
Total Current Liabilities | 2.4M | 315.8M | 56.9M | 18.5M | 32.4M | 57.0M | |
Total Stockholder Equity | (49.6M) | 547.8M | 710.1M | 640.6M | 555.2M | 434.1M | |
Other Liab | 95K | 36K | 5.9M | 5.3M | 6.0M | 6.3M | |
Net Tangible Assets | (49.6M) | 547.8M | 710.1M | 640.6M | 736.7M | 398.8M | |
Property Plant And Equipment Net | 41K | 48K | 23K | 4.1M | 3.1M | 3.3M | |
Net Debt | (21.7M) | (850.1M) | (764.2M) | (643.6M) | (141.4M) | (148.5M) | |
Retained Earnings | (54.2M) | (65.2M) | 56.0M | (59.9M) | (195.8M) | (186.0M) | |
Accounts Payable | 548K | 60K | 4.5M | 2.6M | 4.3M | 2.3M | |
Cash | 21.7M | 850.1M | 764.4M | 646.7M | 143.8M | 136.6M | |
Cash And Short Term Investments | 21.7M | 850.1M | 764.4M | 646.7M | 578.1M | 530.8M | |
Common Stock Shares Outstanding | 82.6M | 82.4M | 88.2M | 83.2M | 83.4M | 85.7M | |
Liabilities And Stockholders Equity | 22.1M | 863.6M | 772.9M | 666.7M | 595.0M | 541.8M | |
Non Current Liabilities Total | 69.2M | 36K | 5.9M | 7.7M | 7.4M | 7.0M | |
Other Current Assets | 249K | 7.5M | 8.0M | 14.2M | 12.3M | 7.8M | |
Other Stockholder Equity | 4.6M | 612.9M | 654.0M | 701.1M | 750.7M | 500.0M | |
Total Liab | 71.6M | 315.8M | 62.8M | 26.1M | 39.8M | 78.3M | |
Net Invested Capital | (49.6M) | 547.8M | 710.1M | 640.6M | 555.2M | 434.1M | |
Property Plant And Equipment Gross | 41K | 48K | 184K | 4.4M | 3.8M | 4.0M | |
Total Current Assets | 21.9M | 863.5M | 772.4M | 660.9M | 590.5M | 539.7M | |
Net Working Capital | 19.5M | 547.7M | 715.5M | 642.4M | 558.1M | 461.3M | |
Property Plant Equipment | 41K | 48K | 23K | 4.1M | 4.7M | 4.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atea PharmaceuticalsI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atea PharmaceuticalsI's short interest history, or implied volatility extrapolated from Atea PharmaceuticalsI options trading.
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
0.73 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Atea Stock
0.53 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.52 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
0.44 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.